Ioanna Xagoraris
E-postadress: ioanna.xagoraris@ki.se
Besöksadress: BioClinicum J6:20, Akademiska stråket 1, 17164 Solna
Postadress: K7 Onkologi-Patologi, K7 Forskning Rassidakis, 171 77 Stockholm
Artiklar
- Article: BMC CANCER. 2025;25(1):959
- Journal article: BLOOD. 2024;144:2999
- Article: NATURE COMMUNICATIONS. 2024;15(1):1752
- Article: CURRENT RESEARCH IN TRANSLATIONAL MEDICINE. 2023;71(3):103401
- Journal article: HEMATOLOGICAL ONCOLOGY. 2023;41 Suppl 2:318
- Journal article: HEMATOLOGICAL ONCOLOGY. 2023;41(S2):677
- Journal article: HEMASPHERE. 2022;6(Suppl ):15-16P032: Circulating immune biomarkers in classical Hodgkin lymphoma in relation to tumor burden and response to treatment.
- Journal article: HEMASPHERE. 2022;6(Suppl ):23-24P052: Targeting CSN5/JAB1 oncogene in classical Hodgkin Lymphoma (cHL)
- Journal article: HEMASPHERE. 2022;6(Suppl ):24P053: The cGAS-STING anti-tumor immune response pathway as a potential therapeutic target in classical Hodgkin Lymphoma (cHL)
- Journal article: HEMASPHERE. 2022;6(Suppl ):53P114: Very late relapses in patients with Hodgkin Lymphoma occuring ≥5 years after initial treament with chemotherapy ± radiotherapy: Treatment strategies and prognostic factors for the outcome
- Journal article: HEMASPHERE. 2022;6(Suppl ):1168-1169P1283: CIRCULATING IMMUNE CELLS IN CLASSICAL HODGKIN LYMPHOMA IN RELATION TO TUMOR BURDEN AND TREATMENT
- Journal article: HEMASPHERE. 2022;6(Suppl ):2041-2042PB2171: THE NOVEL CSN5/JAB1 INHIBITOR CSN5I-3 SUPPRESSES CELL GROWTH AND UPREGULATES GENE EXPRESSION OF TYPE-I INTERFERONS (IFN) IN ANAPLASTIC LARGE CELL LYMPHOMA (ALCL)
- Article: CANCERS. 2022;14(5):1186
- Article: LEUKEMIA & LYMPHOMA. 2021;62(7):1563-1573
- Article: BRITISH JOURNAL OF HAEMATOLOGY. 2021;193(3):488-496
- Journal article: HEMASPHERE. 2019;3(S1):490-491
- Journal article: BLOOD. 2018;132(Supplement 1):4136
- Article: BLOOD CANCER JOURNAL. 2018;8(11):98
Alla övriga publikationer
- Letter: LEUKEMIA. 2025;39(7):1787-1790
- Doctoral thesis: 2025
- Conference publication: HEMATOLOGICAL ONCOLOGY. 2023;41(S2):258
- Conference publication: HEMASPHERE. 2022;6(Suppl ):1189-1190P1304: THE NOVEL TUMOR SUPPRESSOR SAMHD1 CONTRIBUTES TO ANTI-TUMOR RESPONSES IN A CGAS-STING-DEPENDENT OR INDEPENDENT PATHWAY IN HODGKIN LYMPHOMA (HL)
- Conference publication: LABORATORY INVESTIGATION. 2022;102(SUPPL 1):1040-1041
- Conference publication: MODERN PATHOLOGY. 2022;35(SUPPL 2):1040-1041
- Meeting abstract: BLOOD. 2021;138:3515
- Meeting abstract: BLOOD. 2021;138:1338
- Letter: ANNALS OF HEMATOLOGY. 2020;99(3):649-651
- Conference publication: LABORATORY INVESTIGATION. 2019;99
- Conference publication: MODERN PATHOLOGY. 2019;32
- Meeting abstract: BLOOD. 2018;132:4130
- Meeting abstract: BLOOD. 2018;132
- Conference publication: BLOOD. 2017;130
- Conference publication: BLOOD. 2017;130
- Conference publication: HAEMATOLOGICA. 2014;99:695
- Conference publication: HAEMATOLOGICA. 2014;99:403
Anställningar
- Klinisk tjänst, ME Patologi & Cancerdiagnostik, Karolinska Universitetssjukhuset
Examina och utbildning
- PhD, The role of SAMHD1 and cGAS-STING associated anti-tumor response mechanisms in lymphomas, Onkologi-Patologi, Karolinska Institutet, 2025